SCHEMBL30523741

SCHEMBL30523741

CC(C)(C)OC(=O)N1CC2CC(CCO)CC2C1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.77
JAK1 P23458 2/20 0.41
JAK2 O60674 1/20 0.41
NAMPT P43490 1/20 0.40
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
HPGD P15428 1/20 0.37
EPHX2 P34913 1/20 0.37
KDM4E B2RXH2 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
BRD4 O60885 1/20 0.36
PDE4B Q07343 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30376062 1.00 NR1H2 (0.77) NR1H2JAK1JAK2NAMPTUSP2
SCHEMBL25025541 1.00 NR1H2 (0.77) NR1H2JAK1JAK2NAMPTUSP2
Hydrochloric Acid SCHEMBL25258353 0.91 NR1H2 (0.64) NR1H2JAK1JAK2NAMPTEPHX2
SCHEMBL25025883 0.88 NR1H2 (0.72) NR1H2JAK1JAK2NAMPTUSP2
SCHEMBL2993190 0.87 NR1H2 (1.00) NR1H2JAK1JAK2NAMPTUSP2
SCHEMBL20936805 0.87 NR1H2 (1.00) NR1H2JAK1JAK2NAMPTUSP2
SCHEMBL23406722 0.87 NR1H2 (1.00) NR1H2JAK1JAK2NAMPTUSP2
SCHEMBL372106 0.87 NR1H2 (1.00) NR1H2JAK1JAK2NAMPTUSP2
SCHEMBL903882 0.87 NR1H2 (1.00) NR1H2JAK1JAK2NAMPTUSP2
SCHEMBL20031473 0.87 NR1H2 (1.00) NR1H2JAK1JAK2NAMPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118613473-A Compounds and compositions for treating disorders associated with STING activity 艾福姆德尤股份有限公司 2024-09-06 CN disclosed
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 NR1H2 972/4885JAK1 393/4885JAK2 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.